Evidence map of 41 human studies finds mixed effects on next-generation epigenetic clocks

What the research found

Commentary (systematic evidence map). Adiv A. Johnson and David A. Sinclair review in Frontiers in Genetics (doi 10.3389/fgene.2026.1836446) 41 human studies of interventions on next-generation epigenetic aging clocks. Signals of clock decrease were reported for exercise, a plant-rich diet, caloric restriction, omega-3 fatty acids, a multivitamin-multimineral, the GLP-1 receptor agonist semaglutide, and the statin pitavastatin, among others. Nicotinamide riboside, rapamycin, and senolytics showed no detectable clock effect in the mapped studies; plasmapheresis and some other therapeutics were associated with clock acceleration. Clock change is not proof of age reversal or a disease outcome. Semaglutide is a prescription medicine, not a supplement. This is not a reason to start, stop, or replace any prescribed drug. Educational aging-biomarker notes, not medical advice.

Evidence level: Animal study. Results in animals or cells often don't carry over to people.

Not medical advice. Not a substitute for a prescribed medicine. Off-label prescription use is clinician-only. VitaLonga does not diagnose, treat, or cure disease. Never start, stop, or replace a prescription with a supplement on the basis of a headline.

Read the original at Frontiers in Genetics